Schering Likely To Play Up Saphris' Safety In Q4 Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Clearance for schizophrenia and bipolar disorder in one fell swoop marks a first in the crowded class of atypical anti-psychotics.